Description
Rebreath is a nebuliser solution containing Revefenacin INN 175 mcg per 3 ml ampoule. It is indicated for the maintenance treatment of patients with Chronic Obstructive Pulmonary Disease (COPD). Revefenacin is a long-acting muscarinic antagonist (LAMA) that works by inhibiting the M3 receptor at the smooth muscle in the airways, leading to bronchodilation and improved airflow.:
-
Recommended Dose: One ampoule (175 mcg) inhaled once daily using a standard jet nebuliser with a mouthpiece.
-
Route: Oral inhalation via nebuliser.
-
Note: Do not swallow or inject the solution.
-
Special Populations: Not recommended for use in children and adolescents under 18 years. No dosage adjustment is required for patients with renal impairment. Safety has not been established in patients with hepatic impairment.
Precautions:
-
Do not initiate treatment during acutely deteriorating or life-threatening episodes of COPD.
-
Use with caution in patients with narrow-angle glaucoma or urinary retention.
-
Avoid coadministration with other anticholinergic-containing drugs.
Side Effects:
-
Common: Cough, runny nose, upper respiratory tract infection, headache.
-
Serious: Glaucoma, eye pain, blurred vision, painful urination, rash, swelling of the face, mouth, and tongue.
.png)
.webp)
.jpeg)
.jpeg)
.png)
.webp)
.webp)
.jpeg)
.png)
Change Language